Please use this identifier to cite or link to this item:
|Title:||THE PHOSPHODIESTERASE-5 INHIBITORS AND PROSTATE CANCER-WHAT WE RELY KNOW ABOUT IT?|
|Abstract:||Phosphodiesterase-5 inhibitors (PDE5Is) represent a group of drugs that are registered for the treatment of erectiledysfunctions predominantly, but recently also for treatment of pulmonary hypertension and benign prostatic hypertrophy. However, more and more research deals with possible antitumor potential of PDE5Is in different types of cancers, including prostate cancer. Prostate cancer represents theone of the most common carcinoma in the male population, whose incidence is continuously increasing. Early detection combined with radical prostatectomy increases the survival rate, but also it is necessary to keep in mind the quality of life of patients undergoing prostatectomy in light of bladder control and erectile function. Authors of various clinical studies presented the results that often lead to totally opposing conclusions. For example, Chavez and colleagues have shown that use of PDE5Is in men with erectile dysfunction decreases the risk of developing prostate cancer, while, on the other hand, Michl and colleagues pointed out the adversely effect of PDE5Is on biochemical recurrence after bilateral nerve sparing radical prostatectomy. In that sense, the aim of this review was to present as many as possible of existing results dealing with of action of PDE5Is in the field of prostatic carcinoma. Taking into account all presented data, it can be concluded that effect of PDE5Is on formation, development andoutcome of treatment in patients with prostate carcinoma isvery intriguing question, whose response requires additionalboth experimental and clinical research.|
|Appears in Collections:||Faculty of Medical Sciences, Kragujevac|
Files in This Item:
|10.1515_sjecr-2017-0073.pdf||437.36 kB||Adobe PDF|
Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.